Bimagrumab (BYM338): dosing
Human schedule
Bimagrumab (BYM338) is a monoclonal antibody that in clinical studies was given mainly by intravenous infusion. The table below is a generalized reference to regimens described in phase I–II studies.
This is a concise reference to regimens described for adults; it is not an individual prescription.
| Period / condition | Dose | Escalation |
|---|---|---|
| Early studies (phase I) | 210–700 mg IV every 4 weeks | Starting dose |
| Main phase II regimen | 10 mg/kg (max 1200 mg) IV every 4 weeks | Increase if needed |
| Later studies | 10–30 mg/kg IV every 12 weeks | Maximum in this schedule |